KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Castle Biosciences (CSTL) Payables: 2018-2025

Historic Payables for Castle Biosciences (CSTL) over the last 7 years, with Sep 2025 value amounting to $12.2 million.

  • Castle Biosciences' Payables rose 79.31% to $12.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $40.8 million, marking a year-over-year increase of 13.52%. This contributed to the annual value of $6.9 million for FY2024, which is 32.79% down from last year.
  • As of Q3 2025, Castle Biosciences' Payables stood at $12.2 million, which was down 7.36% from $13.2 million recorded in Q2 2025.
  • Castle Biosciences' Payables' 5-year high stood at $13.2 million during Q2 2025, with a 5-year trough of $1.4 million in Q2 2021.
  • Over the past 3 years, Castle Biosciences' median Payables value was $9.3 million (recorded in 2024), while the average stood at $9.2 million.
  • Per our database at Business Quant, Castle Biosciences' Payables slumped by 45.17% in 2021 and then surged by 200.57% in 2023.
  • Castle Biosciences' Payables (Quarterly) stood at $2.5 million in 2021, then surged by 85.82% to $4.7 million in 2022, then spiked by 117.04% to $10.3 million in 2023, then slumped by 32.79% to $6.9 million in 2024, then surged by 79.31% to $12.2 million in 2025.
  • Its Payables was $12.2 million in Q3 2025, compared to $13.2 million in Q2 2025 and $8.5 million in Q1 2025.